CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences.

Details

Serval ID
serval:BIB_15537C0B1F5C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences.
Journal
Clinical Cancer Research
Author(s)
Romero P., Dutoit V., Rubio-Godoy V., Liénard D., Speiser D., Guillaume P., Servis K., Rimoldi D., Cerottini J.C., Valmori D.
ISSN
1078-0432
Publication state
Published
Issued date
2001
Peer-reviewed
Oui
Volume
7
Number
3 Suppl.
Pages
766-772
Language
english
Abstract
We have shown previously that HLA-A*0201 melanoma patients can frequently develop a CTL response to the cancer testis antigen NY-ESO-1. In the present study, we have analyzed in detail the relative antigenicity and in vitro immunogenicity of natural and modified NY-ESO-1 peptide sequences. The results of this analysis revealed that, although suboptimal for binding to the HLA-A*0201 molecule, peptide NY-ESO-1 157-165 is, among natural sequences, very efficiently recognized by specific CTL clones derived from three melanoma patients. In contrast, peptides NY-ESO-1 157-167 and NY-ESO-1 155-163, which bind very strongly to HLA-A*0201, are recognized less efficiently. In agreement with previous data, substitution of peptide NY-ESO-1 157-165 COOH-terminal C with various other amino acids resulted in a significantly increased binding to HLA-A*0201 molecules as well as in an increased CTL recognition, although variable at the clonal level. Among natural peptides, NY-ESO-1 157-165 and NY-ESO-1 157-167 exhibited good in vitro immunogenicity, whereas peptide NY-ESO-1 155-163 was poorly immunogenic. The fine specificity of interaction between peptide NY-ESO-1 C165A, HLA-A*0201, and T-cell receptor was analyzed at the molecular level using a series of variant peptides containing single alanine substitutions. The findings reported here have significant implications for the formulation of NY-ESO-1-based vaccines as well as for the monitoring of either natural or vaccine-induced NY-ESO-1-specific CTL responses in cancer patients.
Keywords
Antigens, Antigens, Neoplasm, Binding, Competitive, CD8-Positive T-Lymphocytes, Cell Separation, Dose-Response Relationship, Drug, Flow Cytometry, HLA-A2 Antigen, Humans, Interferon-gamma, Melanoma, Membrane Proteins, Microscopy, Fluorescence, Peptides, Protein Binding, Proteins, Tumor Cells, Cultured
Pubmed
Web of science
Create date
28/01/2008 11:13
Last modification date
20/08/2019 12:44
Usage data